Literature DB >> 21123731

Chronically elevated glucose compromises myocardial mitochondrial DNA integrity by alteration of mitochondrial topoisomerase function.

S Medikayala1, B Piteo, X Zhao, J G Edwards.   

Abstract

Mitochondrial dysfunction has a significant role in the development and complications of diabetic cardiomyopathy. Mitochondrial dysfunction and mitochondrial DNA (mtDNA) mutations are also associated with different types of cancer and neurodegenerative diseases. The goal of this study was to determine if chronically elevated glucose increase in mtDNA damage contributed to mitochondrial dysfunction and identify the underlying basis for mtDNA damage. H9c2 myotubes (a cardiac-derived cell line) were studied in the presence of 5.5, 16.5, or 33.0 mM glucose for up to 13 days. Tests of mitochondria function (Complex I and IV activity and ATP generation) were all significantly depressed by elevated media glucose. Intramitochondrial superoxide and intracellular superoxide levels were transiently increased during the experimental period. AnnexinV binding (a marker of apoptosis) was significantly increased after 7 and 13 days of high glucose. Thirteen days of elevated glucose significantly increased mtDNA damage globally and across the region encoding for the three subunits of cytochrome oxidase. Using mitochondria isolated from cells chronically exposed to elevated glucose, we observed significant increases in topoisomerase-linked DNA cleavage. Mitochondria-dependent DNA cleavage was significantly exacerbated by H(2)O(2) and that immunoprecipitation of mitochondrial extracts with a mtTOP1 antibody significantly decreased DNA cleavage, indicating that at least part of this activity could be attributed to mtTOP1. We conclude that even mild increases in glucose presentation compromised mitochondrial function as a result of a decline in mtDNA integrity. Separate from a direct impact of oxidative stress on mtDNA, ROS-induced alteration of mitochondrial topoisomerase activity exacerbated and propagated increases in mtDNA damage. These findings are significant in that the activation/inhibition state of the mitochondrial topoisomerases will have important consequences for mitochondrial DNA integrity and the well being of the myocardium.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21123731      PMCID: PMC3043634          DOI: 10.1152/ajpcell.00248.2010

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  72 in total

1.  Molecular analyses of mtDNA deletion mutations in microdissected skeletal muscle fibers from aged rhesus monkeys.

Authors:  Nolan G Gokey; Zhengjin Cao; Jeong W Pak; Damian Lee; Susan H McKiernan; Debbie McKenzie; Richard Weindruch; Judd M Aiken
Journal:  Aging Cell       Date:  2004-10       Impact factor: 9.304

2.  Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphoblastic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.

Authors:  Abdullah Büyükçelik; Bülent Yalçin; Güngör Utkan; Hatice Doruk
Journal:  Cancer       Date:  2004-09-01       Impact factor: 6.860

3.  Mitochondrial DNA damage triggers mitochondrial-superoxide generation and apoptosis.

Authors:  Craig Ricci; Viktor Pastukh; Josh Leonard; Julio Turrens; Glenn Wilson; David Schaffer; Stephen W Schaffer
Journal:  Am J Physiol Cell Physiol       Date:  2007-12-12       Impact factor: 4.249

4.  Clinical value of glycated hemoglobin and fructosamine in the long-term glycemic control of children with acute lymphoblastic leukemia.

Authors:  S Yetgin; S S Yalçin; N Ozbek
Journal:  Acta Paediatr Jpn       Date:  1998-02

5.  Absence of a pyrimidine dimer repair mechanism for mitochondrial DNA in mouse and human cells.

Authors:  D A Clayton; J N Doda; E C Friedberg
Journal:  Basic Life Sci       Date:  1975

6.  The rate of mitochondrial mutagenesis is faster in mice than humans.

Authors:  E Wang; A Wong; G Cortopassi
Journal:  Mutat Res       Date:  1997-07-03       Impact factor: 2.433

7.  The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.

Authors:  Lonnie P Swift; Suzanne M Cutts; Abraham Nudelman; Inessa Levovich; Ada Rephaeli; Don R Phillips
Journal:  Cancer Chemother Pharmacol       Date:  2007-06-27       Impact factor: 3.333

8.  A novel peroxisome proliferator-activated receptor alpha/gamma agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells.

Authors:  Yu-Hsun Kao; Hsing-Pang Hsieh; Santhosh Kumar Chitlimalla; Wen-Yu Pan; Ching-Chuan Kuo; Yuan-Chin Tsai; Wen-Hsing Lin; Shuang-En Chuang; Jang-Yang Chang
Journal:  Anticancer Drugs       Date:  2008-02       Impact factor: 2.248

9.  Accumulation of somatic mutation in mitochondrial DNA and atherosclerosis in diabetic patients.

Authors:  Takashi Nomiyama; Yasushi Tanaka; Lianshan Piao; Nobutaka Hattori; Hiroshi Uchino; Hirotaka Watada; Ryuzo Kawamori; Shigeo Ohta
Journal:  Ann N Y Acad Sci       Date:  2004-04       Impact factor: 5.691

Review 10.  Bioenergetics of mitochondrial diseases associated with mtDNA mutations.

Authors:  Giorgio Lenaz; Alessandra Baracca; Valerio Carelli; Marilena D'Aurelio; Gianluca Sgarbi; Giancarlo Solaini
Journal:  Biochim Biophys Acta       Date:  2004-07-23
View more
  18 in total

1.  Chronic ethanol consumption increases myocardial mitochondrial DNA mutations: a potential contribution by mitochondrial topoisomerases.

Authors:  D Laurent; J E Mathew; M Mitry; M Taft; A Force; J G Edwards
Journal:  Alcohol Alcohol       Date:  2014-05-22       Impact factor: 2.826

Review 2.  Mitochondrial allostatic load puts the 'gluc' back in glucocorticoids.

Authors:  Martin Picard; Robert-Paul Juster; Bruce S McEwen
Journal:  Nat Rev Endocrinol       Date:  2014-03-25       Impact factor: 43.330

3.  Poisoning of mitochondrial topoisomerase I by lamellarin D.

Authors:  Salim Khiati; Yeonee Seol; Keli Agama; Ilaria Dalla Rosa; Surbhi Agrawal; Katherine Fesen; Hongliang Zhang; Keir C Neuman; Yves Pommier
Journal:  Mol Pharmacol       Date:  2014-06-02       Impact factor: 4.436

4.  Obesity-associated extracellular mtDNA activates central TGFβ pathway to cause blood pressure increase.

Authors:  Albert Alé; Yalin Zhang; Cheng Han; Dongsheng Cai
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-11-15       Impact factor: 4.310

Review 5.  Role of p53 in neurodegenerative diseases.

Authors:  J Robert Chang; Mohammad Ghafouri; Ruma Mukerjee; Asen Bagashev; Tinatin Chabrashvili; Bassel E Sawaya
Journal:  Neurodegener Dis       Date:  2011-10-28       Impact factor: 2.977

6.  Accelerated cardiomyocyte senescence contributes to late-onset doxorubicin-induced cardiotoxicity.

Authors:  Maria A Mitry; Dimitri Laurent; Britny L Keith; Elizabeth Sira; Carol A Eisenberg; Leonard M Eisenberg; Sachindra Joshi; Sachin Gupte; John G Edwards
Journal:  Am J Physiol Cell Physiol       Date:  2020-01-08       Impact factor: 4.249

Review 7.  Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies.

Authors:  Olesya Ilkun; Sihem Boudina
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

8.  Type II diabetes increases mitochondrial DNA mutations in the left ventricle of the Goto-Kakizaki diabetic rat.

Authors:  S Hicks; N Labinskyy; B Piteo; D Laurent; J E Mathew; S A Gupte; J G Edwards
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-02-01       Impact factor: 4.733

9.  Lack of mitochondrial topoisomerase I (TOP1mt) impairs liver regeneration.

Authors:  Salim Khiati; Simone A Baechler; Valentina M Factor; Hongliang Zhang; Shar-yin N Huang; Ilaria Dalla Rosa; Carole Sourbier; Leonard Neckers; Snorri S Thorgeirsson; Yves Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-24       Impact factor: 11.205

10.  After the chemotherapy: potential mechanisms for chemotherapy-induced delayed skeletal muscle dysfunction in survivors of acute lymphoblastic leukaemia in childhood.

Authors:  Celena Scheede-Bergdahl; R Thomas Jagoe
Journal:  Front Pharmacol       Date:  2013-04-19       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.